Do you have trouble sleeping in the morning or in the middle of the night? This can affect your risk of developing dementia.

Published Date: 08 Mar 2023

Along with growing evidence of poor sleep and cognitive impairment, a new study has found an association between three measures of sleep and the risk of developing dementia by age 10. ...

Read Full News

Latest News

Distinguishing Lambert-Eaton Myasthenic Syndrome From Myasthenia Gravis: Ocular and Systemic Clues Isabella Ciccone, MPH

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

NeurologyLive® Friday 5 — October 30, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.

Understanding Advances Shaping Precision Medicine for Generalized Myasthenia Gravis Marco Meglio

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials Isabella Ciccone, MPH

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design Isabella Ciccone, MPH, M. Scott Perry, MD, Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines Louie Pasculli, Talya Fleming, MD, Sara Cuccurullo, MD

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.

Todays Updates

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Deep TMS Reduces Suicidal Ideation by 70% in MDD, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy Marco Meglio

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

This Week on NeurologyLive® — November 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show Marco Meglio, Jeffrey Cohen, MD

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

Todays Updates

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Deep TMS Reduces Suicidal Ideation by 70% in MDD, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy Marco Meglio

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

This Week on NeurologyLive® — November 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show Marco Meglio, Jeffrey Cohen, MD

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

Latest News

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.

News All Time

CORE-VNS Study Shows Sustained Seizure Reduction With VNS Therapy at 36 Months Louie Pasculli

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

This Week on NeurologyLive® — October 26, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Calcium Channel Blockers Linked to Lower Blood Pressure Variability Marco Meglio

A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.

CAR-T Agent Zola-cel Shows No New Multiple Sclerosis Disease Activity in Phase 1 Study Louie Pasculli

Updated data from Breakfree-2 study showed that treatment with a single zola-cel infusion achieved NEDA-3 in highly active relapsing multiple sclerosis and led to mostly stable disability in progressive multiple sclerosis.

Tenecteplase Benefit Before Thrombectomy Varies by Stroke Cause, Study Shows Marco Meglio

A secondary analysis of the BRIDGE-TNK trial found tenecteplase before thrombectomy improved functional outcomes in cardioembolic but not atherosclerotic stroke.

Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS Matt Hoffman, Louie Pasculli

Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.

Houston Forum Highlights Awareness Gaps in NF1 Plexiform Neurofibroma Care Marco Meglio

At a NeurologyLive and Targeted Oncology Clinical Forum in Houston, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how incidental diagnosis and limited awareness of systemic therapy continue to delay care for patients with NF1-associated plexiform neurofibromas.

NeurologyLive® Brain Games: October 25, 2026 Louie Pasculli, Marco Meglio

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent advances in gene therapies.

NeurologyLive® Friday 5 — October 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

Endovascular Therapy Benefit in Distal Vessel Stroke Tied to Severity, Not IVT Status Marco Meglio

A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.

More Time in Target Blood Pressure Range Cuts Recurrent Stroke After Intracerebral Hemorrhage Marco Meglio

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia Marco Meglio

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

Liposomal Mitoxantrone Shows Early Safety Signal in Phase 2 NMOSD Trial Marco Meglio

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Recommended News For You

Routine breast cancer screening can bring better outcomes for patients

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Mammography with AI support is a secure method for detecting breast cancer.

Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.

We Don't Always Know What's 'Best' for Our Patients

Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

Recommended Articles For You

Patient Management After Personalized Surgical Oncology Reconstruction 

Breaking Down Amyloidosis: Understanding the Disease  

Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment 

Pediatric Advances in Long-Term Survivorship Science for Childhood Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.

2.

Black and Hispanic children with high-risk neuroblastoma have worse outcomes despite standardized treatment

3.

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

4.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.

5.

Melanoma Patient on Immunotherapy Develops Severe Dermatitis

1.

Targeting Bone Marrow Immune Niches in Refractory Hematologic Disorders

2.

Cancer Across the Lifespan: Precision Strategies for Pediatric and Geriatric Oncology

3.

Physical Recovery During Cancer Survivorship: Clinical Perspectives and Evidence-Based Approaches

4.

Developmental Platelet Biology in Childhood: Clinical Implications and Advances

5.

CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know

2.

Forecasting Platelet Recovery After Extracorporeal Treatment Through Megakaryocyte Output Dynamics

3.

How Cancer Screening Supports Early Diagnosis

4.

Signs and Symptoms of Leukemia

5.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot